Cerbios-Pharma showcases PROVEO End-to-End CDMO services for ADCs at 13th World ADC London

news-releasesCERBIOS-PHARMA SA
March 13th 2023

London, United Kingdom: – CDMO specialist Cerbios-Pharma SA (Cerbios) will be again a high profile presence at the 13th World ADC in London, highlighting its fully integrated services for ADCs.

Throughout the event, Cerbios will be represented at the PROVEO Booth (n°3) at the ExCel London Conference Center, which has been freshly renewed to make it more aligned with Cerbios new company image, emphasizing an innovative, modern and customer-oriented approach, built around customer-centric customization, modernization and care.

Business Development Team will promote PROVEO, a division of Cerbios-Pharma SA, that offers End-to-End CDMO services for ADCs development and manufacturing, from cell line development and mAbs, to payload, conjugation and aseptic filling.

PROVEO Lunch seminar on Day One

PROVEO is a long-standing partner of World ADC and has become an established presence both as exhibitor and contributor to the scientific agenda. In London, PROVEO will host an invitation-only lunch seminar on Day One of the event (Tuesday, March 14th) that will involve key players in ADC field.

During the Lunch-Seminar, Cerbios R&D Director, Dr. Alberto Terraneo, will present a talk on “Common challenges at the process and analytical level during the development and manufacturing of drug-linkers and ADCs”.

The main topics of the discussion will be:

  • The Critical Process of Technology Transfer;
  • The role of Quality by Design (QbD) in Technology Transfer;
  • Synergies from Integrated Development.

Dr. Terraneo, a PhD in organic chemistry from University of Milan and a specialist in chemical process and analytical development, is responsible for Cerbios-Pharms chemical and biotechnological R&D activities. Alongside Dr. Terraneo, the Cerbios and PROVEO team will include also Cerbios-Pharma SA Director Business Development – CDMO, Vítor Sousa and Business Developer Filippo Caragnano.

About Cerbios-Pharma

Cerbios is a privately held company located in Lugano, Switzerland, specialized in manufacturing Pharma Products and in offering CDMO services.

Cerbios is the ideal CDMO partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Proveo™, a division of Cerbios, was recently created to provide end-to-end development and manufacturing services for ADCs.

Cerbios is also a global leading supplier of a portfolio of Generic APIs primarily used in Oncology and for the treatment of Respiratory and Dermatological disorders. Cerbios has additionally a 40 years’ experience in the probiotics field: the portfolio includes a FDF based on proprietary strain SF68® for treatment of diarrhea and dysbiosis by antibiotics and two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response.

Learn more at: https://cerbios.swiss

About World ADC Europe 2023

The World ADC Conference franchise forms the pharma industry’s most comprehensive and established series of events devoted to Antibody Drug Conjugate technology and solutions.

The 13th World ADC Europe Congress will be a four-day event opening March 13th at the ExCel arena in London’s Docklands with an accompanying online dimension.

The 2023 conference will feature more than 60 hours of content sessions spread across an opening Seminar Day, two Scientific Program Days and a final day devoted to 12 workshops.

The event is organized by Hanson Wade with further information at: https://worldadc-europe.com.


Click on Cerbios-Pharma at World ADC London 2023 to connect with Cerbios at event.


CERBIOS-PHARMA Company Brochure

Cerbios-Pharma showcases PROVEO End-to-End CDMO services for ADCs at 13th World ADC London